ImmuCell Corporation (ICCC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ImmuCell Corporation (ICCC) has a cash flow conversion efficiency ratio of -0.040x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.18 Million) by net assets ($29.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ImmuCell Corporation - Cash Flow Conversion Efficiency Trend (1989–2024)
This chart illustrates how ImmuCell Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ICCC total liabilities for a breakdown of total debt and financial obligations.
ImmuCell Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ImmuCell Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PDS Biotechnology Corp
NASDAQ:PDSB
|
-0.400x |
|
Falcon Machine Tools Co Ltd
TWO:4513
|
-0.035x |
|
biote Corp
NASDAQ:BTMD
|
-0.150x |
|
Wisekey International Holding AG
NASDAQ:WKEY
|
-0.128x |
|
ZEN Graphene Solutions Ltd
NASDAQ:ZTEK
|
-0.103x |
|
Shinih Enterprise Co Ltd
TW:9944
|
0.008x |
|
Tunas Alfin Tbk
JK:TALF
|
0.034x |
|
Sonel S.A.
WAR:SON
|
-0.006x |
Annual Cash Flow Conversion Efficiency for ImmuCell Corporation (1989–2024)
The table below shows the annual cash flow conversion efficiency of ImmuCell Corporation from 1989 to 2024. For the full company profile with market capitalisation and key ratios, see ImmuCell Corporation market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $27.52 Million | $357.90K | 0.013x | +106.95% |
| 2023-12-31 | $24.99 Million | $-4.67 Million | -0.187x | -268.02% |
| 2022-12-31 | $30.38 Million | $-1.54 Million | -0.051x | -273.50% |
| 2021-12-31 | $32.58 Million | $954.17K | 0.029x | -37.07% |
| 2020-12-31 | $28.27 Million | $1.32 Million | 0.047x | +477.85% |
| 2019-12-31 | $28.99 Million | $233.51K | 0.008x | +146.90% |
| 2018-12-31 | $21.74 Million | $-373.40K | -0.017x | -134.46% |
| 2017-12-31 | $23.59 Million | $1.18 Million | 0.050x | +403.43% |
| 2016-12-31 | $19.72 Million | $-323.90K | -0.016x | -106.01% |
| 2015-12-31 | $10.61 Million | $2.90 Million | 0.273x | +736.69% |
| 2014-12-31 | $9.26 Million | $302.36K | 0.033x | -72.07% |
| 2013-12-31 | $9.40 Million | $1.10 Million | 0.117x | +212.19% |
| 2012-12-31 | $9.19 Million | $344.39K | 0.037x | +1005.44% |
| 2011-12-31 | $9.02 Million | $-37.31K | -0.004x | +95.25% |
| 2010-12-31 | $9.28 Million | $-808.61K | -0.087x | -664.32% |
| 2009-12-31 | $9.62 Million | $-109.67K | -0.011x | -306.85% |
| 2008-12-31 | $9.64 Million | $53.14K | 0.006x | -84.15% |
| 2007-12-31 | $10.06 Million | $349.56K | 0.035x | -76.12% |
| 2006-12-31 | $9.33 Million | $1.36 Million | 0.146x | +62.84% |
| 2005-12-31 | $8.56 Million | $764.78K | 0.089x | -49.14% |
| 2004-12-31 | $7.73 Million | $1.36 Million | 0.176x | -7.76% |
| 2003-12-31 | $7.37 Million | $1.40 Million | 0.190x | -30.22% |
| 2002-12-31 | $6.95 Million | $1.90 Million | 0.273x | +82.16% |
| 2001-12-31 | $6.05 Million | $906.00K | 0.150x | +918.37% |
| 2000-12-31 | $5.54 Million | $81.50K | 0.015x | -93.90% |
| 1999-12-31 | $2.82 Million | $679.70K | 0.241x | -11.48% |
| 1998-12-31 | $2.20 Million | $600.00K | 0.273x | +527.27% |
| 1997-12-31 | $2.30 Million | $100.00K | 0.043x | +182.61% |
| 1996-12-31 | $1.90 Million | $-100.00K | -0.053x | -133.33% |
| 1995-12-31 | $1.90 Million | $300.00K | 0.158x | +400.00% |
| 1994-12-31 | $1.90 Million | $-100.00K | -0.053x | -221.05% |
| 1993-12-31 | $2.30 Million | $100.00K | 0.043x | +126.09% |
| 1992-12-31 | $1.80 Million | $-300.00K | -0.167x | +79.17% |
| 1991-12-31 | $1.50 Million | $-1.20 Million | -0.800x | -348.00% |
| 1990-12-31 | $2.80 Million | $-500.00K | -0.179x | -1.19% |
| 1989-12-31 | $3.40 Million | $-600.00K | -0.176x | -- |
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotaviru… Read more